Question explored with the scientific record
Could covid vaccines cause epilepsy
The short version: the evidence shows COVID vaccines can trigger seizures, but epilepsy as a lasting diagnosis is not established by these records.
The retrieved studies document seizures as a real, if rare, post-vaccine event. A 2025 Iranian cohort of nearly 90,000 adults found generalized seizures after Sputnik V and AZD1222, with onset 2 to 23 days after vaccination [5]. A 2024 Mexican pediatric surveillance review of over 1.9 million doses in children aged 5–17 reported 2 seizure cases, plus one case each of spasticity and acute flaccid paralysis [6]. These are passive reports, which detect only a fraction of events, so the true count is likely higher than reported.
The mechanism is plausible. Vaccines provoke a strong immune response, and the same inflammatory cascade that causes documented new-onset autoimmune conditions like lupus, arthritis, and kidney disease [1][2][4] can irritate the brain. Seizures are a known complication of brain inflammation. But epilepsy means recurrent, unprovoked seizures. None of these records follow patients long enough to show that a single post-vaccine seizure becomes epilepsy.
What the retrieval cannot see matters: no study here compares vaccinated people to a genuinely unvaccinated control group for epilepsy risk. The New Zealand study of 12 adverse events found no significant signal for neurological conditions beyond heart inflammation [3], and a Swedish adolescent cohort found no elevated risk of serious events requiring hospitalization [7]. But neither directly measured epilepsy.
| Event | Population | Cases | Rate |
|---|---|---|---|
| Generalized seizure | 89,783 adults, Iran | 5 (Sputnik V, AZD1222) | ~5.6 per 100,000 |
| Seizure | 1.99M doses, children 5–17, Mexico | 2 | ~0.1 per 100,000 |
My call: a single seizure after COVID vaccination is documented but rare; epilepsy as a new chronic condition is not proven by these records. Confidence: low.
Sources used 7
-
New-Onset and Relapsed Kidney Histopathology Following COVID-19 Vaccination: A Systematic Review
This systematic review investigates the occurrence of new-onset and relapsed kidney histopathology following COVID-19 vaccination, highlighting various pathologies such as minimal change disease and IgA nephropathy, and concludes that the benefits of vaccination outweigh the ass…
DOI: 10.3390/vaccines9111252 -
New-Onset Arthritis Following COVID-19 Vaccination: A Systematic Review of Case Reports
This systematic review investigates the incidence and characteristics of new-onset arthritis following COVID-19 vaccination, analyzing 31 studies and 45 cases, predominantly affecting females and linked to adenovirus vector and mRNA vaccines.
DOI: 10.3390/vaccines11030665 -
Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
This nationwide study in New Zealand assessed the association between the BNT162b2 mRNA COVID-19 vaccine and 12 adverse events of special interest, finding a statistically significant increase in myo/pericarditis, particularly among younger individuals, while no significant asso…
DOI: 10.1007/s40264-023-01332-1 -
New-onset systemic lupus erythematosus following BNT162b2 mRNA COVID-19 vaccine: a case series and literature review
This study presents a case series of three male patients who developed new-onset systemic lupus erythematosus following the BNT162b2 mRNA COVID-19 vaccine, highlighting potential immunogenic influences of the vaccine on autoimmune diseases.
DOI: 10.1007/s00296-022-05203-3 -
Adverse events of special interest after vaccination with COVID-19 vaccines: a cohort event monitoring study in Iran
A WHO-guided cohort event monitoring study in Iran assessing adverse events of special interest (AESIs) and serious adverse events (SAEs) after four COVID-19 vaccines (Sinopharm, Sputnik V, AZD1222, and COVIran Barekat) in 89,783 adults across seven cities, finding very rare AES…
DOI: 10.1186/s40001-025-03015-2 -
Eventos adversos por la vacuna COVID-19 Pfizer-BioNTech® en niños de 5-17años
A passive-surveillance review of 52 reported adverse events after BNT162b2 (Pfizer-BioNTech) vaccination in children aged 5–17 years in Puebla, Mexico, in 2022 found an annual rate of 2.6 events per 100,000 doses; nearly all events were non-severe, most were systemic (dizziness,…
DOI: 10.29262/ram.v71i3.1316 -
Safety and effectiveness of monovalent COVID-19 mRNA vaccination and risk factors for hospitalisation caused by the omicron variant in 0.8 million adolescents: A nationwide cohort study in Sweden
In a Swedish nationwide cohort of adolescents, monovalent COVID-19 mRNA vaccination was not associated with elevated risks of serious adverse events leading to hospitalisation, and two doses provided 76% effectiveness against COVID-19 hospitalisation during the omicron period, w…
DOI: 10.1371/journal.pmed.1004127